Key Takeaways:
- Neusoft Medical has taken several twists and turns on the IPO road, reversing out of an earlier bid to join Shanghai’s STAR Market and now making a third attempt to list shares in Hong Kong
- The company’s business picture is dotted with risks from falling R&D spending in relation to revenue, rapidly rising sales costs, and a reliance on distributors
